- US-listed companies
- Mirum Pharmaceuticals, Inc.
- Income statement
Mirum Pharmaceuticals, Inc. (MIRM) Income statement
Market cap
$5.8B
P/E ratio
| 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | - | 19 | 77 | 186 | 337 |
| Revenue growth (%) | - | - | - | |||
| Selling, general & administrative | - | - | - | 89 | 146 | 202 |
| Operating margin (%) | - | - | ||||
| Operating expenses | 55 | 104 | 193 | 208 | 296 | 424 |
| Operating income | -55 | -104 | -173 | -131 | -109 | -88 |
| Income before tax | -53 | -103 | -84 | -142 | -162 | -87 |
| Pretax margin (%) | - | - | -438.7 | -184.4 | -87.1 | -25.8 |
| Provision for income taxes | 0 | 0 | 0 | -6 | 1 | 1 |
| Effective tax rate (%) | ||||||
| Net income | -53 | -103 | -84 | -136 | -163 | -88 |
| Net income margin (%) | - | - | ||||
| Earnings per share | - | - | - | -4.01 | -4 | -1.85 |
| Diluted EPS | - | - | - | -4.02 | -4 | -1.85 |
| EBITDA | ||||||
| EBITDA margin (%) | - | - |